基于Pyrazole的蛋白激酶抑制剂的最新进展作为新兴的治疗点
1Department of Chemistry, Faculty of Education, Van Yüzüncü Yil University, Van, 65080, Turkey.
Combinatorial chemistry & high throughput screening
|November 10, 2023
概括
皮拉 - 脚手架蛋白激酶抑制剂 (PKIs) 对癌症和神经疾病具有治疗潜力. 这篇评论详细介绍了它们的设计,特性和发展,为药物发现提供了洞察力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 皮拉-脚手架蛋白激酶抑制剂 (PKIs) 正在研究用于治疗癌症,炎症和神经系统疾病.
- 这些抑制剂表现出不同的药理性质,包括作用机制,选择性,效力和毒性.
- 突出了最近在PKI设计和合成中的Pyrazole-Scaffold进步,重点是结构-活动关系.
研究的目的:
- 为了提供Pyrazole-Scaffold PKI的全面概述.
- 总结最近在它们的设计,合成和药理学评估方面的进展.
- 讨论临床前和临床发现,包括疗效,安全性和药理动力学.
主要方法:
- 在USPTO,EPO和WIPO数据库中进行了系统的专利搜索.
- 搜索集中在"pyrazole"作为2015年至2022年期间提交的专利的关键词.
- 纳入标准指定蛋白质激酶抑制剂和具有药理活性的pyrazole衍生物.
主要成果:
- 提取的数据包括专利名称,号码,发明人,权所有人以及提交/发布日期.
- 系统记录了专利类型和发明领域的信息.
- 标准化表格确保了所有审查的专利数据的一致性和准确性.
结论:
- 含有皮拉的化合物被设计和评估为生物活性物质,特别是作为蛋白激酶抑制剂.
- 关键结构及其药理数据是详细的,为药物开发提供了洞察力.
- 该审查涉及治疗应用中pyrazole-scaffold PKI发展的当前挑战和未来方向.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
13:22Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
7.9K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Protein Kinases and Phosphatases
13.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.2K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
G Protein-coupled Receptors
12.2K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.2K
